Journal of Clinical Pharmacy and Therapeutics 2014-10-01

Concentrations of venlafaxine and its main metabolite O-desmethylvenlafaxine during pregnancy.

P G J ter Horst, K H M Larmené-Beld, J Bosman, E L van der Veen, A Wieringa, J P Smit

Index: J. Clin. Pharm. Ther. 39(5) , 541-4, (2014)

Full Text: HTML

Abstract

Depression during pregnancy is common and includes risks for mother and child. Pharmacokinetics of venlafaxine may be changed during pregnancy. This study aimed to describe changes in metabolic ratios and concentrations of venlafaxine and its main metabolite O-desmethylvenlafaxine during and after pregnancy.To study this, we used data from our study of compliance to Antidepressants During Pregnancy (the ADAP study) to investigate the course of venlafaxine and O-desmethylvenlafaxine concentrations during pregnancy and in the period post-partum.We found that the venlafaxine concentration significantly changed during pregnancy when compared to the post-partum period (P = 0·028). The median concentration of venlafaxine in the first trimester was 98·9% (54·2-292·0%), the second 100·0% (46·5-264·0%) and the third trimester 87·0% (61·5-217·2%). We did not found differences in O-desmethylvenlafaxine concentrations in the different trimesters of pregnancy compared with the post-partum period, P = 0·565. Also the ratio of O-desmethylvenlafaxine/venlafaxine concentrations increased significantly from 76·9% (range 32·8-142·0%) in the first trimester to 196·7% (range 83·3-427·6%) in the third trimester compared with the post-partum period, P = 0·004. Further, three of seven patients had concentrations below the therapeutic reference range (100-400 μg/L) in any period of pregnancy, whereas no one had subtherapeutic concentrations in the post-partum period.Venlafaxine concentrations decreases during pregnancy, and the ratio of the concentrations of O-desmethylvenlafaxine/venlafaxine increases during pregnancy. Pregnant women using venlafaxine are at risk for subtherapeutic concentrations, therefore routine monitoring of concentrations venlafaxine and O-desmethylvenlafaxine is recommendable during pregnancy.© 2014 John Wiley & Sons Ltd.


Related Compounds

Related Articles:

Neuroprotective effect of modified Chungsimyeolda-tang, a traditional Korean herbal formula, via autophagy induction in models of Parkinson's disease.

2015-01-15

[J. Ethnopharmacol. 159 , 93-101, (2014)]

Biomolecular imaging with a C60-SIMS/MALDI dual ion source hybrid mass spectrometer: instrumentation, matrix enhancement, and single cell analysis.

2014-11-01

[J. Am. Soc. Mass Spectrom. 25(11) , 1897-907, (2014)]

Methionine oxidation accelerates the aggregation and enhances the neurotoxicity of the D178N variant of the human prion protein.

2014-12-01

[Biochim. Biophys. Acta 1842(12 Pt A) , 2345-56, (2014)]

Quantification of furanic derivatives in fortified wines by a highly sensitive and ultrafast analytical strategy based on digitally controlled microextraction by packed sorbent combined with ultrahigh pressure liquid chromatography.

2015-02-13

[J. Chromatogr. A. 1381 , 54-63, (2015)]

Silencing urease: a key evolutionary step that facilitated the adaptation of Yersinia pestis to the flea-borne transmission route.

2014-12-30

[Proc. Natl. Acad. Sci. U. S. A. 111(52) , 18709-14, (2014)]

More Articles...